News MedicalHighly-Sensitive Blood Test Detects Hidden Traces of Pancreatic Cancer

⚠️ Early Evidence Signal

Pancreatic cancer has high recurrence rates even after surgery and chemotherapy, largely due to undetected minimal residual disease (MRD). Standard next-generation sequencing (NGS)–based liquid biopsy approaches often lack sensitivity in low-shedding tumors.

Clinical Considerations

• ddPCR detected tumor DNA in 65% of patients vs 17% with NGS at diagnosis
• Detection persisted post-treatment (~60% after chemotherapy, ~56% after surgery)
• Identified a previously unrecognized high-risk cohort:
  • NGS-negative but ddPCR-positive
  • Median survival 27 months vs 41 months in double-negative patients
• Enables mutation-aligned monitoring, particularly relevant for emerging KRAS-targeted therapies
• Findings are based on single-center data (n=106) and require validation

Practice Applications

• Expect under-detection with standard NGS assays in pancreatic cancer
• Mutation-specific ctDNA assays may improve MRD detection
• Potential future integration:
  • Serial ctDNA monitoring
  • Earlier intervention at molecular recurrence
• Clinical adoption remains premature pending validation